CTLA4 and neoplasm: Ahmedi et al., demonstrated that utilizing temperature- dependent transcriptional repressors, TlpA39 and Tcl42 in the clinically approved E. coli Nissle 1917 (EcN) could lead to a temperature regulated release of anti CTLA-4 and anti PD-L1 antibodies resulting in A20 tumor retardation in a murine model (114).